Quantcast

Latest Cambridge Antibody Technology Stories

2011-01-06 15:09:00

THOUSAND OAKS, Calif. and MONROVIA, Calif., Jan. 6, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) and Xencor, Inc. announced today that they will collaborate to develop XmAb(®)5871, an Fc- engineered monoclonal antibody dually targeting CD19 and CD32b. XmAb5871 is currently in late-stage preclinical development for the treatment of autoimmune diseases. Under the terms of the agreement, Amgen has the option to an exclusive worldwide license following the completion of a...

2010-12-07 04:00:00

BURLINGAME, Calif., Dec. 7, 2010 /PRNewswire/ -- Apexigen, Inc. announced today that it has entered into a collaboration and worldwide license agreement with Centocor Research & Development, Inc. and its affiliates to utilize Apexigen's proprietary therapeutic antibody technologies to discover and develop monoclonal antibody drugs. Apexigen will generate and screen antibodies to several targets specified by Centocor R&D, which will be responsible for development and...

2010-11-22 04:30:00

THOUSAND OAKS, Calif., Nov 22, 2010 /PRNewswire/ -- ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics with numerous anti-cancer functions built into a single therapy, announced today that it has received a $244,479 grant under The Patient Protection and Affordable Care Act of 2010 (PPACA). The grant was related to the development of ImmunGene's technology which is based on antibody-cytokine fusions that have demonstrated targeted toxicity...

2010-11-16 08:00:00

GAITHERSBURG, Md., Nov. 16, 2010 /PRNewswire/ -- Today, MedImmune announced that researchers will present data from its oncology portfolio, including new clinical data, at two upcoming medical congresses in Europe and the United States. "At MedImmune, we are thinking about cancer and treatment in new ways, using insights and understanding of the disease to discover breakthrough biologic therapies that can be used to treat specific cancers for the individual patient," said Jerry McMahon,...

2010-10-18 07:00:00

PLANTATION, Fla., Oct. 18 /PRNewswire/ -- Goodwin Biotechnology, Inc., a full service contract biomanufacturing company, today announced that it has signed a new Biopharmaceutical Development and Manufacturing Agreement with a multinational biopharmaceutical client. According to the agreement, Goodwin will develop the process to manufacture a unique therapeutic monoclonal antibody conjugate for diagnostic imaging purposes. This product will be manufactured under cGMP conditions as a kit...

2010-08-12 14:50:00

BURLINGAME, Calif., Aug. 12 /PRNewswire/ -- Epitomics, Inc. today announced that it has spun-out to its shareholders a new biotechnology company called Apexigen, Inc., which will focus on the development and commercialization of humanized monoclonal antibodies for treatment of cancer and immuno-disorders. Apexigen was formed with exclusive rights to develop and commercialize therapeutic monoclonal antibodies derived from Epitomics RabMAb® (Rabbit Monoclonal Antibody)...

2010-08-12 11:36:00

BANNOCKBURN, Ill., Aug. 12 /PRNewswire/ -- The Board of Directors of Pinnacle Biologics Inc. has appointed Mr. James L. Foght PhD as a director of the corporation, effective July 28, 2010. Dr. Foght has over 40 years experience in the healthcare and life science industries. He was a co-founder of DuPont Pharmaceuticals and the founder and President of Vector Securities International, a premier investment banking firm specializing in life sciences. He is currently chairman of the Board of...

2010-07-11 18:00:00

LONDON, July 12, 2010 /PRNewswire/ -- MRC Technology (UK) announced today that it has entered into an agreement with Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) for an exclusive licence to a series of small molecule drug candidates for the potential treatment of neurological disease. This is the first small molecule chemistry programme to come out of MRC Technology's Centre for Therapeutics Discovery (CTD) and the first major small molecule...

2010-02-03 18:01:00

LONDON, February 4 /PRNewswire/ -- A major centre created by the Medical Research Council (MRC) and MRC Technology (MRCT) in order to fast-track the discovery and development of novel drugs, opens its first call for targets today. The MRCT Centre for Therapeutics Discovery (CTD), based in London, is seeking small molecule drug discovery and therapeutic antibody targets from academic researchers. The CTD would like to collaborate with scientists in all universities to develop...

2009-12-07 11:56:00

NEW YORK, Dec. 7 /PRNewswire/ -- Royalty Pharma is pleased to announce that Alexander von Perfall has joined the company as Vice President, Investor Relations. (Logo: http://www.newscom.com/cgi-bin/prnh/20061026/RPLOGO) Alexander has 13 years of cross-border management advisory, strategic planning and principal investment experience, most recently as co-founder and Chief Network Officer of XTF, a start-up Exchange Traded Funds Ratings Agency. He previously advised the International...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related